» Articles » PMID: 15730114

Pharmacists' and Technicians' Perceptions and Attitudes Toward Dispensing Buprenorphine/ Naloxone to Patients with Opioid Dependence

Overview
Publisher Elsevier
Specialties Pharmacology
Pharmacy
Date 2005 Feb 26
PMID 15730114
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess the perceptions and attitudes of pharmacists and pharmacy technicians involved in an office-based opioid dependence treatment program using buprenorphine/naloxone.

Design: Cross-sectional attitudinal assessment.

Setting: Community, outpatient hospital, and clinic pharmacies.

Participants: Pharmacists and technicians participating in a clinical trial of opioid dependence treatment using buprenorphine/naloxone.

Intervention: Written and telephone surveys followed by interviews with open-ended items.

Main Outcome Measures: Attitudes and perceptions regarding opioid-dependent patients and use of buprenorphine/naloxone for treatment of opioid dependence.

Results: Pharmacies in seven states (New York, Virginia, Illinois, Florida, Texas, California, and Washington) participated in the clinical trial. A total of 40 pharmacists and pharmacy technicians responded to the initial written survey, representing 27 of the 32 pharmacies (84%). Follow-up interviews were obtained from one individual at 30 of those pharmacies (93.8%). Most pharmacy personnel (77.5%) involved with this study were not more concerned about theft or break-ins and would be willing to participate in opioid dependence treatment as the medication became available commercially (70%). The majority of respondents (85%) indicated that patients did not cause problems at their pharmacies. Compared with their experiences in administering other narcotic medications, most respondents did not express increased concern regarding prescription forgery (75%) or diversion (80%) of buprenorphine/naloxone.

Conclusion: The majority of respondents expressed positive attitudes and perceptions regarding patients treated for opioid dependence with buprenorphine/naloxone.

Citing Articles

Development of a brief stigma and perceptions questionnaire for pharmacists: An exploratory factor analysis approach in New York state counties enrolled in the healing communities study.

Goddard-Eckrich D, Grealis K, El-Bassel N, Lounsbury D, Dsouza N, Bhuiyan J J Subst Use Addict Treat. 2024; 169:209566.

PMID: 39527983 PMC: 11769743. DOI: 10.1016/j.josat.2024.209566.


Predictors of concurrent heroin use among patients on opioid maintenance treatment in France: a multilevel study over 11 years.

Janssen E, Vuolo M, Spilka S, Airagnes G Harm Reduct J. 2024; 21(1):15.

PMID: 38243253 PMC: 10799399. DOI: 10.1186/s12954-024-00934-x.


Community-Centered Patient Journey Map in Opioid Use Disorder: A Tool to Address Compassion Fatigue among Community Pharmacists.

Hohmeier K, Cernasev A, Leibold C, Moore T, Schlesinger E, Cochran G Pharmacy (Basel). 2023; 11(2).

PMID: 36961030 PMC: 10037586. DOI: 10.3390/pharmacy11020052.


Impact of a Multicomponent Educational Intervention on Community Pharmacy-Based Naloxone Services Implementation: A Pragmatic Randomized Controlled Trial.

Hohmann L, Fox B, Garza K, Wang C, Correia C, Curran G Ann Pharmacother. 2022; 57(6):677-695.

PMID: 36047381 PMC: 10310292. DOI: 10.1177/10600280221120405.


Factors associated with perceived ease of access to syringes in Appalachian North Carolina.

Carpenter D, Zule W, Hennessy C, Evon D, Hurt C, Ostrach B J Rural Health. 2022; 39(1):212-222.

PMID: 35819251 PMC: 9772148. DOI: 10.1111/jrh.12698.